Unimark has invested 4.5 million dollars in R&D, which is quite rare for a company that is mostly focused on APIs. "We will
be investing at least another $10 million in the next couple of years to achieve this. At that point we will have reached
an adequate standard that will enable us to start talking about contract research with innovative partners," says Parekh.
Today, Indian generics and API companies represent about four percent of the world market. This means there is still 96 percent
of the market available. "Considering that our closest competition comes from China and that no Chinese company is integrated—they
specialize in either APIs or generics, but not both—I believe Indian companies will play a more important role and become
more profitable in the future," concludes Parekh.
Lupin: number one for anti-tuberculosis
API is the core business of Lupin. In India, the company has a portfolio of more than 200 formulations in various segments.
It is one of the world's largest manufacturers of drugs that combat tuberculosis, bacterial infection, and cardiovascular
"When I started the company in 1968, I realized that the disease that killed the most people in India and the world was—and
still is—tuberculosis," says Dr. Desh Bandhu Gupta, Chairman of Lupin. "So we decided to start working in that area and today
we are the number one producers of Anti-TB drugs in the world. Furthermore, we are currently working on a new molecule against
Dr. Gupta expects Lupin to become a billion dollar company by 2009
Lupin was the first in India to manufacture Anti-TB APIs. "This earned for us the respect of our peers and we soon went on
to become a front runner for the title of world leaders in Anti-TB drug manufacturing," recalls Dr. Gupta.
Lupin's range of formulation is marked by brand leadership across various several segments, for it believes that its branded
business possesses significant potential to not just improve patient treatment but also address unmet medical needs.
At the beginning of 2006, Lupin signed a memorandum of understanding with ASPEN for the establishment of a joint venture.
Huge product synergies are expected, for Lupin has traditional strengths in Anti-TB formulations and APIs, and ASPEN will
bring a range of multi-drug resistant TB (MDR-TB) products to the venture. "We believe there is a large space for extending
our cooperation with ASPEN. This first joint venture will serve us to generate the core of the relationship, to better understand
each other. We are planning to go further as the potentiality for cooperation is immense," Dr. Gupta explains.
As a part of the global strategy to increase its participation in the high margin / high value advanced markets of US and
EU, Lupin over the years created the right infrastructure by upgrading its facilities to globally accredited regulatory standards
and invested in R&D to introduce a product pipeline specific to the market requirements. Lupin has entered into an alliance
with Watson Pharmaceutical to market its Cefuroxime Axetil tablet in the United States. It has also entered into an agreement
with Baxter Healthcare Corporation, by which Baxter will exclusively distribute Lupin's generic version of Ceftriaxone sterile
vials for injection in the US post-patent approval.
Unimark Remedies Ltd.
It's no wonder that by the end of March 2009, Dr. Gupta expects to become a $1 billion dollar company. "I am confident we
will achieve this goal," he claims. "In terms of research, we have four molecules under different stages of development. We
also have three DDS platform patents. Regarding APIs and dosages, whatever we decide to manufacture we are either number one
or number two in the world. We know the job."